Hematología y Hemoterapia

Resultados: 470
Tipo Título / Nombre Autor(es) Año
Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival Valhondo I, Pera A, Hassouneh F..., Bergua JM, Arcos MJ, Casas-Avilés I, et al 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW..., Bergua Burgués JM, et al 2025
Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study Solana-Altabella A, Navarro-Vicente I, Rodríguez-Arbolí E, Noriega V, Serrano J..., Bergua-Burgues JM, et al 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry Alfonso-Pierola A, Martinez-Cuadrón D, Rodríguez-Veiga R, Gil C, Gil C, Gil C, et al 2025
Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry Colmenares R, Álvarez N, Barragán E, Boluda B, Larrayoz MJ..., Bergua J, et al 2025
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience Serrano J, Martínez-Cuadrón D, Gil C, Gil C, Gil C, Bernal T, et al 2025
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, et al 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study Westin J, Tycel JP, Amitkumar M..., Bergua Burgués JM 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS DeZern AE, Thepot S, De Botton S, Patriarca A, Deeren D..., Bergua Burgues JM, et al 2025
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy Manubens A, Paiva B, Gutiérrez NC, , et al 2025